Latest news with #Tevimbra
&w=3840&q=100)
Business Standard
7 hours ago
- Business
- Business Standard
Glenmark Pharmaceuticals shares up 3% on launching cancer drug Tevimbra
Glenmark Pharmaceuticals share price today: Pharmaceutical major Glenmark Pharmaceuticals shares rose as much as 2.74 per cent to hit an intraday high of ₹1,728 per share on Wednesday, June 25, 2025. Around 1:05 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 1.82 per cent at ₹1,712.50 per share. In comparison, BSE Sensex was trading 0.71 per cent higher at 82,636.70 levels. Why did Glenmark Pharmaceuticals share price rise today? Glenmark Pharmaceuticals share price gained in trade after the company announced the launch of Tevimbra (tislelizumab) in India, following approval by the Central Drugs Standard Control Organisation (CDSCO). Tevimbra is a uniquely engineered anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology innovator focused on delivering cutting-edge cancer therapies. The drug is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy, and as a second-line monotherapy for both locally advanced/metastatic NSCLC and esophageal squamous cell carcinoma (ESCC). The launch marks Glenmark Pharmaceuticals' entry into the immuno-oncology space in India and is a key step in broadening its oncology portfolio with innovative therapies. NSCLC accounts for over 80 per cent of all lung cancer cases, while ESCC is the most prevalent histological subtype of esophageal cancer in India. Tevimbra addresses the major treatment needs of this large patient base with a differentiated and evidence-backed option, the company said. Already approved and available in major markets including the US, EU, Australia, and China, Tevimbra is designed to selectively bind to PD-1 receptors, restoring T-cell function and limiting off-target immune suppression. It has shown strong efficacy and a favourable safety profile across various solid tumors in multiple Phase 3 studies and a global clinical programme. Glenamark Pharmaceuticals Q4 results For the fourth quarter of FY2024-25 (Q4FY25), Glenmark Pharmaceuticals reported a consolidated revenue of ₹3,256.2 crore, marking a year-on-year (Y-o-Y) growth of 6.3 per cent from ₹3,063 crore in the same period last year. The company's Ebitda for the quarter stood at ₹560.7 crore, up 11.2 per cent from ₹504.3 crore, with an Ebitda margin of 17.2 per cent. Adjusted Profit After Tax (PAT) for the quarter came in at ₹346.6 crore, reflecting an adjusted PAT margin of 10.6 per cent. For the full fiscal year ended March 31, 2025 (FY25), the company's consolidated revenue rose 12.8 per cent to ₹13,321.7 crore, compared to ₹11,813.1 crore in the previous year. Ebitda for FY25 more than doubled to ₹2,351 crore from ₹1,195.3 crore, with the Ebitda margin improving to 17.6 per cent. The company also posted an adjusted PAT of ₹1,389.4 crore for the year, resulting in an adjusted PAT margin of 10.4 per cent. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-driven global pharmaceutical company with a strong presence across Branded, Generics, and OTC segments. The company focuses on key therapeutic areas including respiratory, dermatology, and oncology. With 11 state-of-the-art manufacturing facilities spread across four continents and operations in over 80 countries, Glenmark Pharmaceuticals has established itself as a major player in the global pharmaceutical landscape. The market capitalisation of Glenmark Pharmaceuticals is ₹48,171.68 crore, according to BSE. The company falls under the BSE 500 index. Glenmark Pharmaceuticals' 52-week high is ₹1,830.05 per share, while its 52-week low is ₹1,199.95 apiece.
Business Upturn
12 hours ago
- Business
- Business Upturn
Top stocks in focus on June 25: JB Chemicals, Infosys, PTC Industries, HAL, IRCTC, and more
By Aman Shukla Published on June 25, 2025, 08:21 IST The Indian stock market is set for an eventful session on Wednesday, June 25, with several companies announcing fresh developments that could draw investor attention. Here's a look at key corporate news and updates that may influence stock movement: JB Chemicals received US FDA approval for its generic Amitriptyline Hydrochloride tablets, expanding its regulated market portfolio. Infosys announced a strategic tie-up with Zoetis, aimed at boosting IT and digital operations using AI and automation solutions. Aurobindo Pharma's subsidiary CuraTeQ Biologics received marketing approval in the UK for Dyrupeg, a biosimilar of pegylated filgrastim. Servotech Renewable won a ~16 MW rooftop solar project from Madhya Pradesh Urja Vikas Nigam Ltd, strengthening its clean energy pipeline. PTC Industries' subsidiary Aerolloy Technologies signed an MoU with Safran Aircraft Engines to develop a domestic manufacturing ecosystem for military aircraft engines. Bajel Projects secured a large substation order in India valued between Rs 1–2 billion. Glenmark Pharmaceuticals launched lung cancer drug Tevimbra in the Indian market. IndiGo reported a slight rise in market share for May, climbing to 64.6% from 64.1% the previous month. KFin Technologies reappointed Vishwanathan Mavila Nair as Chairman for a one-year term starting October 1, 2025. IRCTC is likely to be in focus as Indian Railways prepares for a nationwide fare hike across all passenger categories starting July 1. HAL confirmed that the Indian Air Force will receive at least six Tejas fighter jets by March 2026. Bondada Engineering landed a Rs 836 crore order for battery energy storage systems from Tamil Nadu Green Energy Corporation, to be executed over 12 years. Ashok Leyland announced plans to expand its commercial vehicle footprint by adding 50 new outlets in North India. Hindalco said its US-based subsidiary, Aditya Holdings LLC, will acquire AluChem Companies Inc., a specialty alumina producer, for $125 million. India Glycols reported record-high sales of its alcoholic beverage brand 'Bunty Bubbly' for FY24–25. Supreme Infrastructure secured a Rs 4.5 billion turnkey project in Mumbai, taking its total order book to Rs 17.25 billion. Rites received a letter of intent for a Rs 28.5 crore infrastructure project from Gujarat Urban Development Company. CWD Ltd announced an initial order worth Rs 8 crore from a leading digital services provider. Several companies reported key management changes, including India Gelatine, Kabra Extrusion, Rathi Steel, Vibhor Steel, and National Plastic, all involving resignations of company secretaries or senior officers. Enviro Infra received a GST department notice over tax dues totaling Rs 8.4 crore for the period FY19–FY24. Vodafone Idea clarified that it has not received any formal communication from the government regarding potential relief on its outstanding dues. CIE Automotive will invest Rs 2.6 crore to acquire up to 29% in AMP Energy C&I Thirty Two Private Ltd. Petronet LNG, Ador Welding, and Automobile Corporation of Goa announced record dates for their final dividends. India Cements, Mahindra & Mahindra, Bharat Bijlee, and HSCL reported credit rating updates and investment activities that may influence their respective valuations. Lloyd Metals completed the acquisition of a 26.82% stake in HR Godavari Private Limited for Rs 17.4 crore. Mastek said CFO Raghavendra Jha will step down on July 11, 2025. Kaynes Technology closed its Qualified Institutional Placement, issuing 28.73 lakh shares at Rs 5,569.50 per share. BLS E-Services announced it will acquire customer service points of SBI and HDFC Bank through its subsidiary under a deal worth around Rs 6.5 crore. Union Bank of India revoked the appointment of Pankaj Dwivedi as Executive Director with immediate effect. Dredging Corporation of India was removed from the Short-Term Additional Surveillance Measure (ASM) list. Several companies are trading ex-date today, including Elitecon International (stock split), Quest Capital, Aegis Logistics, and Automobile Corporation of Goa (dividends). Infibeam Avenues is scheduled to open its rights issue tomorrow, June 26. CG Power received a tax notice from the Income Tax Department proposing an additional liability of Rs 1,194.54 crore following a draft assessment order. Timex Group promoters are looking to offload a 15% stake in the India unit via an Offer for Sale at Rs 175 per share. Tata Motors may see global headwinds as Jaguar Land Rover faces potential exposure of up to £1.6 billion due to proposed US tariffs. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash HALInfosysIRCTCJB ChemicalsPTC IndustriesStock Market Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
12 hours ago
- Business
- Business Standard
Stocks to Watch today: Union Bank, Hindalco, Vi, JB Chemicals, TaMo, Rites
Stocks to Watch Today, Wednesday, June 25, 2025: Indian equity markets are set to extend their positive momentum as the fragile truce between Iran and Israel appears to hold. Tensions in West Asia were under control after US President Donald Trump criticised both nations for breaching ceasefire agreements, just hours after they were agreed upon. That said, the early indicator of Nifty50 performance -- GIFT NIFTY -- was up 109 points or 0.44 per cent at 25,181 as of 7:50 AM. Track LIVE Updates Here Stock markets in Asia edged higher, taking cues from a strong close on Wall Street. Last checked, Japan's Nikkei was higher by 0.16 per cent, and South Korea's Kospi was up 0.3 per cent. Meanwhile, equities in the US were buoyed by easing tensions in West Asia, along with comments on potential rate cuts from Federal Reserve Chair Jerome Powell. Lower inflation and weaker labour hiring could lead to an earlier rate cut, Powell said, while the impact of trade tariffs has to be weighed. The S&P 500 index rose by 1.11 per cent, while the Dow Jones Industrial Average closed 1.19 per cent higher. Back home, on Tuesday, the BSE Sensex settled 158.32 points or 0.19 per cent higher at 82,055.11, while the Nifty50 rose 72.45 points or 0.29 per cent to end at 25,044.35. FIIs sold shares worth ₹5,266.01 crore, while DIIs net bought equities worth ₹5,209.6 crore. Meanwhile, below are some stocks to watch during today's session: Union Bank of India: The government has cancelled the appointment of Pankaj Dwivedi, one of the executive directors of the state-owned lender. Dwivedi, who was a general manager in Punjab & Sind Bank, was appointed as executive director of Union Bank in March last year, for a period of three years. Hindalco Industries: The Aditya Birla Group company announced the acquisition of a 100 per cent equity stake in US-based AluChem for $125 million. The deal will be executed through Aditya Holdings LLC, a step-down wholly owned subsidiary of Hindalco. The acquisition is expected to close in the next quarter. Vodafone Idea: The company said that it has not received any official communication from the government regarding relief on its ₹84,000 crore adjusted gross revenue (AGR) dues, despite reports suggesting that such relief is under consideration. Tata Motors: The auto major said that export restrictions on rare-earth magnets imposed by China have not yet disrupted its production pipeline, and the company is actively exploring alternate sources and technologies. Glenmark Pharmaceuticals: The pharma major said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation. Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. Aurobindo Pharma: The firm's subsidiary CuraTeQ Biologics received UK MHRA approval for Dyrupeg, its third biosimilar nod after Bevqolva and Zefylti, following earlier EU clearance in April 2025. JB Chemicals & Pharmaceuticals: The pharma company received US Food and Drug Administration (USFDA) approval for its ANDA of Amitriptyline Hydrochloride Tablets (10–150 mg), a generic antidepressant indicated for the relief of depression symptoms. BLS E-Services: The company, via subsidiary Zero Mass, signed a definitive agreement to acquire SBI and HDFC Bank Customer Service Points (CSPs) on a slump sale basis for ₹6.5 crore. This is to expand financial inclusion and enhance last-mile banking service delivery across India Himadri Speciality Chemical: The firm's board approved the acquisition of a 16.24 per cent stake in US-based International Battery Company for $4.43 million, comprising stock purchase from an existing shareholder and subscription to common and preferred shares. Rites: The company received a Letter of Intent (LoI) from Gujarat Urban Development Company for a ₹28.5 crore contract to serve as TPI agency for WSS/UGD/STP projects under Amrut 2.0/SJMMSVY over 60 months. Zydus Wellness: The company's board approved the voluntary liquidation of its subsidiary Naturell (India) Private Limited and cleared its consolidation with the parent entity to simplify the structure and drive synergies and operational efficiencies. PTC Industries: The company's subsidiary, Aerolloy Technologies Limited (ATL) and Safran Aircraft Engines inked a Memorandum of Understanding (MoU) to develop cooperation on the manufacturing of components and materials for military aircraft engines.
&w=3840&q=100)
Business Standard
a day ago
- Business
- Business Standard
Glenmark Pharma launches lung cancer treatment drug Tevimbra in India
Glenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation. Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing. "At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact," Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that "Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients". Tevimbra is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and oesophagal squamous cell carcinoma (ESCC) as monotherapy, the company said. It is approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
